Alexion Pharmaceuticals Inc. is set to go to market with Ultomiris (ALXN-1210, ravulizumab), the long-acting C5 complement inhibitor approved by the FDA Friday nearly two months ahead of its Feb. 18, 2019, PDUFA date to treat adults with the ultra-rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH).